🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to researchers.

An International Challenge

The sexually transmitted infection are increasing globally, with figures suggesting over 82 million infections each year. Especially elevated rates are seen in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Public health authorities are deeply concerned about the surge in drug-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Approval

One new antibiotic, alternatively called a brand name, was approved by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts believe that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in concurrent days. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a unique collaborative effort for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This approval marks a major breakthrough in the management of highly resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Data and Global Access

According to data published in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an comparable level with the current standard treatment, which combines two antibiotics. The research enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to register and commercialise the drug in many developing nations.

Doctors directly involved have expressed optimism. The availability of a one-pill regimen of this kind is seen as a "game-changer" for public health efforts. This is considered crucial to alleviate the strain of the illness for people and to halt the transmission of extremely resistant gonorrhoea around the world.